

18–20°C, since pronounced temperature variations were found to alter the duration of THAO tremor. Mice were housed in groups of 12 and randomly assigned to the treatment groups. 6 mice were used in each group. The presence of tremor was assessed by observation of the 4 limbs when the mice were lying on their side and when held up in the cupped hand. The degree of tremor for each animal was observed by a trained observer who was unaware of the pretreatment regimen and scored on a scale of 1–3, with 1 representing mild tremor and 3 the most severe tremor. The mice were also observed for loss of righting reflex, ptosis and other vital signs. The statistical significance of the differences in duration of tremor was assessed by the Student's nonpaired t-test. Thiophene-2-carboxaldehyde oxime was purchased from Aldrich Chemical Company, Inc. It was dissolved extemporaneously in dimethylsulfoxide to make a 10% solution and injected i.p. in volumes not exceeding 0.1 ml. Control animals given an equivalent volume of solvent showed no tremor. All other drugs were prepared as fresh solutions in saline and injected i.p., except haloperidol (Haldol), reserpine (Serpasil), Clonidine (Catapress) and chlorimipramine (Anafranil) where proprietary parenteral solutions were used.

The results are summarized in the table. A dose of THAO (175 mg/kg) which was found in previous experiments² to be the threshold dose which produced tremor and loss of righting reflex in all mice (ED 100) was administered to saline-pretreated mice. These served as controls. Pretreatment of mice with agents which are known to alter the content of serotonin or its actions in the central nervous system (5-hydroxytryptophan, p-chlorophenylalanine, cinanserin) failed to affect the intensity and duration of tremor significantly.

A wide spectrum of substances which interact with brain catecholamines was tested. Agents which deplete catecholamines (alpha-methyl p-tyrosine, reserpine) or antagonize their central actions (haloperidol, chlorpromazine) significantly increased the intensity and duration of the tremor and the loss of righting reflex. Conversely, pretreatment with agents which enhance catecholaminergic tone (apomorphine, pargyline, d-amphetamine, chlorimipramine, ephedrine, L-dihydroxyphenylalanine, but not clonidine) reduced the duration and intensity of tremor. The most effective agent, aside from d-amphetamine, was apomorphine. In view of the evidence for dopamine receptor stimulation by apomorphine³, its antagonism of THAO tremor implicates a dopaminergic mechanism. This is further supported by the enhancement of this tremor by haloperidol, an agent shown to possess marked dopamine receptor blocking action⁶. However, an adrenergic component may also be operative, since the monoamine oxidase inhibitor pargyline and the antidepressant chlorimipramine were moderately effective in reducing the tremor.

- 1 This project was supported by a grant from the Lebanese National Research Council. We thank the following companies for the indicated drugs: Abbott (pargyline), Specia (chlorpromazine), Squibb (cinanserin).
- 2 N.R. Banna and R. Kurkjian, *Brain Res.* 87, 114 (1975).
- 3 G.M. Everett, *Nature* 177, 1238 (1956).
- 4 J.M. Van Rossum, *Int. Rev. Neurobiol.* 12, 307 (1970).
- 5 N.-E. Andén, A. Rubenson, K. Fuxe and T. Hokfelt, *J. Pharm. Pharmacol.* 19, 627 (1967).
- 6 N.-E. Andén, S. Butcher, H. Corrodi, K. Fuxe and U. Ungerstedt, *Eur. J. Pharmacol.* 11, 303 (1970).

Kinetics of transformation of aflatoxin B₁ into aflatoxin M₁ in lactating mouse: An ELISA analysis

Y. K. Li and F. S. Chu^{1,2}

Department of Food Microbiology and Toxicology, and Food Research Institute, University of Wisconsin-Madison, Madison (Wisconsin 53706, USA), 18 March 1981

Summary. A new enzyme-linked immunosorbent assay (ELISA) was used to study the kinetics of transformation of aflatoxin B₁ into aflatoxin M₁ in lactating mice. Aflatoxin M₁ concentration in the milk samples reached a maximum 30 min after injection of aflatoxin B₁ and decreased thereafter. At the maximum time, the levels of aflatoxin M₁ in the samples were proportional to the dosages administered. Aflatoxin B₁ was also detected in the milk samples but at a lower concentration.

Aflatoxin M₁ (afla M₁) is one of the major aflatoxin B₁ (afla B₁) metabolites produced by a number of animal species and has been found in animal livers, urine, feces and milk^{3–7}. Since afla M₁ was found to be toxic as well as carcinogenic to test animals^{8–10}, the presence of this toxin in cow's milk has been considered to be potentially hazardous to human health. A rigorous regulatory program for afla M₁ in foods has been established in the U.S. as well as in other countries. The extent of afla M₁ contamination in dairy products and the impact of afla M₁ on human and animal health have been recently reviewed¹¹. Since the discovery of excretion of afla M₁ in the milk of cows consuming afla B₁ contaminated feeds, considerable efforts have been made by various investigators to elucidate the mechanism and kinetics of transformation of afla M₁ in to afla B₁ in animals and its subsequent excretion into the milk^{12,13}. Most excretion studies were done with large animals including cows, sheep and ewes^{7,11–13}. Studies with small animals such as rats¹⁴ and mice were hindered by the unavailability of a suitable analytical

method to detect these metabolites in a small amount of milk. Recent developments on the immunochemical assay of aflatoxins in our laboratory and others^{15–18} have led to a sensitive, simple and specific microplate enzyme-linked immunosorbent assay (ELISA) for afla M₁ in which as little as 0.25 ppb of afla M₁ in a 25 µl of milk sample can be readily detected¹⁸. With the availability of this method, we have selected mouse as the test animal to carry out the present study. The objectives of this study are 2-fold: a) to test the feasibility of using this new ELISA procedure for metabolic studies and b) to analyze the kinetics of transformation of afla B₁ into afla M₁ in the lactating mice.

A colony of lactating mice (strain-HA/ICR, Sprague Dawley, Madison, WI) with an average size of 50 g was divided into 2 groups (4–5 mice each). Mice in the 1st group were injected i.p. with 5 µg each of pure afla B₁ prepared according to the method of Chu¹⁹ and mixed with a small amount of ³H-afla B₁ (Moravsek Biochemicals, City of Industries, CA) in 0.1 ml dimethylsulfoxide. The

specific activity of the final mixture was 1400 dpm/ng aflatoxin B₁. In the 2nd group, a dose of 50 µg aflatoxin B₁ without ³H-aflatoxin B₁ was used for each. Milk samples were collected before administering aflatoxin B₁ and at appropriate times after injection using the procedure of Nagasawa²⁰ except that no anesthesia was applied to the test animals before milking. For each mouse, approximately 0.2 ml of milk was collected every time. The milk samples from different mice were pooled, and if necessary diluted to an appropriate concentration (0.5–1.0 ng/ml) with sodium phosphate buffer (0.1 M, pH 7.4) and then subjected directly to the ELISA according to the procedures previously described¹⁸. For aflatoxin B₁, antisera against aflatoxin B₁ and horseradish peroxidase conjugated with aflatoxin B₁ were used¹⁶. Likewise, aflatoxin M₁ antisera and horseradish peroxidase conjugated with aflatoxin M₁ were used in the ELISA of aflatoxin M₁ (Pestka et al.¹⁸). Triplicate analyses were made for each sample. The radioactivity of the samples was measured in a Beckman Model LS 330 scintillation counter and corrected for background and counting efficiency (25–35%) by a channels ratio method.

Results for the transformation of aflatoxin B₁ into aflatoxin M₁ in the lactating mouse after injection of aflatoxin B₁ are given in the table. To test the validity of our ELISA data, mice in 1 group were injected with ³H-aflatoxin B₁. Aflatoxins were extracted from the 30 min milk sample with methanol:chloroform (1:9 ratio, 10× vol., 2 times), and then subjected to TLC using adsorbent 5 as the absorbent (Applied Science, State College, PA, USA) and developed in chloroform:acetone (9:1). External standards of aflatoxin B₁ and M₁ were spotted simultaneously with the sample. After development, materials in the aflatoxin B₁ and M₁ spots were scraped from the plates and the radioactivity determined. The results showed that 4.2 ng/ml (5862 dpm/ml) of aflatoxin M₁ and 2.2 ng/ml (3125 dpm/ml) aflatoxin B₁ were present in the 30 min sample. The concentration of aflatoxin M₁ determined by the TLC method was approximately 60% of that of the ELISA. The lower value obtained by the TLC method might be due to losses in the extraction step and/or to using an inadequate specific radioactivity in the estimation. Since excellent recovery of aflatoxin M₁ added to cow's milk has been obtained by ELISA in our previous investigations, we believe that the ELISA result is more accurate than the TLC method.

In the present study, we found that aflatoxin M₁ concentration in the milk reached the maximum 30 min after injection of 50 µg of aflatoxin B₁ and decreased thereafter. The amount of aflatoxin M₁ in the 30 min milk samples appears to be directly proportional to the dosage administered. The maximum concentration of aflatoxin M₁ (63.3 ng/ml) in the milk of mice injected with 50 µg of aflatoxin B₁ per mouse (1000 µg/kg b.wt) is almost 10 times higher (63.3 vs 7 ng/ml) than those injected with 5 µg. Based on these data, the

relationship between the maximum aflatoxin M₁ concentration in milk and the amount of aflatoxin B₁ administered was estimated to be 60–70 ng aflatoxin M₁ per ml with every mg aflatoxin B₁ per kg b.wt administered. It is interesting to note that this value is similar to the data obtained from cows. Allcroft et al.¹² found that the highest amount of aflatoxin M₁ in cow's milk was around 14–15 ng/ml when a cow of 600 kg size was fed a single dose of aflatoxin mixture containing 132 mg of aflatoxin B₁ (220 µg aflatoxin B₁/kg b.wt). Although the present data cannot be directly compared to the study with cows because of the difference in route of administration and the species difference, as the cow has a rumen and the degradation of aflatoxin B₁ occurs in the rumen and omasum²¹, the similarity of the maximum aflatoxin M₁ concentrations in milk further supports the hypothesis that 'liver' is the major organ for conversion of aflatoxin B₁ into M₁ and that the cow rumen does not play a significant role in this transformation.

In conclusion, the present study demonstrates that the ELISA for aflatoxin B₁ and M₁ developed in our laboratory is adequate for the metabolic study of conversion of aflatoxin B₁ to M₁. Since only a small amount of sample is required for the analysis, this approach could be used to monitor aflatoxin M₁ and B₁ in human milk in certain areas where aflatoxin B₁ has been found in food and where a high incidence of liver cancer has been documented. Direct epidemiological correlation between liver cancer incidence and aflatoxin consumption might then be obtainable. Since significant amounts of aflatoxin B₁ have been detected in mice, the lactating mouse and weanling mouse could be used as an animal model system to study the effect of aflatoxin B₁ and M₁ on weanling animals.

Recovery of aflatoxins B₁ and M₁ in mouse milk after administration of aflatoxin B₁ to lactating mice

Time (h)	Dose A (5 µg/mouse)	Dose B (50 µg/mouse)	Aflatoxin B ₁ (ng/ml)
	Aflatoxin M ₁ (ng/ml)	Aflatoxin M ₁ (ng/ml)	
0	0	0	0
0.5	7.0 ± 0.6	63.3 ± 4.3	— ^a
1	—	54.0 ± 1.1	7.0 ± 0 (6.4) ^b
3	2.0 ± 0.2	32.0 ± 1.7	5.4 ± 0.5 (5.9)
5	—	12.8 ± 1.7	—
8	0.7 ± 0.0	—	—
10	—	12.0 ± 2.3	3.1 ± 0.7 (4.0)
24	0.6 ± 0.1	1.6 ± 0.1	—

^aNot analyzed; ^bvalues in parentheses in this column indicate the ratio of aflatoxin M₁/aflatoxin B₁.

- Supported by the College of Agricultural and Life Sciences, the University of Wisconsin-Madison and by Public Health Service research grant No. CA 15064 from the National Cancer Institute, NIH.
- The authors wish to thank Dr J.J. Pestka for his suggestions in the preparation of this manuscript and Dr Hon-Peng Lau for his help in the preparation of aflatoxin-horseradish peroxidase conjugates.
- R. Allcroft and R.B.A. Carnagham, *Vet. Rec.* 75, 259 (1963).
- I.F.H. Purchase and L.J. Vorster, *S. Afr. med. J.* 42, 219 (1970).
- J.R. Hayes, C.E. Polan and T.C. Campbell, *J. agric. Fd Chem.* 25, 1189 (1977).
- D.S.P. Patterson, *Pure appl. Chem.* 49, 1723 (1977).
- J.V. Rodricks and L. Stoloff, in: *Aflatoxin residues from contaminated feed in edible tissues of food-producing animals*, p. 67. Eds J.V. Rodricks, C.W. Hesseltine and M.A. Mehlman. Pathotox Publishers Inc., Park Forest So., Ill. 1977.
- I.F.H. Purchase, *Fd Cosmet. Toxic.* 5, 339 (1967).
- G.N. Wogan and S. Pagliarunga, *Fd Cosmet. Toxic.* 12, 381 (1974).
- J.H. Canton, R. Kroes, M.J. van Logten, M. van Schothorst, J.F.C. Stavenuiter and C.A.H. Verhulsdonk, *Fd Cosmet. Toxic.* 13, 441 (1975).
- L. Stoloff, *J. Fd Prot.* 43, 226 (1980).
- R. Allcroft, B.A. Roberts and M.K. Lloyd, *Fd Cosmet. Toxic.* 6, 619 (1968).
- C.E. Polan, J.R. Hayes and T.C. Campbell, *J. agric. Chem.* 22, 635 (1974).
- H. de Jongh, R.O. Vles and J.G. van Pelt, *Nature* 202, 466 (1964).
- W.O. Harder and F.S. Chu, *Experientia* 35, 1104 (1979).
- J.J. Pestka, P.K. Gaur and F.S. Chu, *Appl. envir. Microbiol.* 40, 1027 (1980).
- A. Biermann and G. Terplan, *Arch. Lebensmittelhyg.* 31, 51 (1980).
- J.J. Pestka, Yaguan Li, W.O. Harder and F.S. Chu, *J. Ass. off. analyt. Chem.* 64, 294 (1981).
- F.S. Chu, *J. Ass. off. analyt. Chem.* 54, 1034 (1971).
- H. Nagasawa, *Lab. Anim. Sci.* 29, 633 (1979).
- G. Engel and H. Hagemister, *Milchwissenschaft* 33, 21 (1978).